Financials data is unavailable for this security.
View more
Year on year Nurix Therapeutics Inc grew revenues 99.31% from 38.63m to 76.99m while net income improved from a loss of 180.36m to a smaller loss of 143.95m.
| Gross margin | -- |
|---|---|
| Net profit margin | -313.65% |
| Operating margin | -343.30% |
| Return on assets | -43.07% |
|---|---|
| Return on equity | -57.96% |
| Return on investment | -52.51% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Nurix Therapeutics Inc fell by 9.85m. However, Cash Flow from Investing totalled 68.30m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 81.37m for operations while cash generated from financing totalled 3.22m.
| Cash flow per share | -2.75 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 5.62 |
|---|---|
| Tangible book value per share | 5.62 |
More ▼
Balance sheet in USDView more
| Current ratio | 5.28 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
